Cataract surgery remains the most commonly performed surgery worldwide, with nearly 28 million procedures taking place each year. Yet, despite its prevalence, only a small percentage of patients—around 10 to 15%—receive advanced intraocular lenses (IOLs) designed to address presbyopia and astigmatism. Johnson & Johnson’s latest innovation, the TECNIS PureSee™ IOL, aims to change that reality.
This year, the technology was recognized at the 2025 MedTech Breakthrough Awards, receiving the title of “Best New Technology Solution – Ophthalmology.” The award highlights how the TECNIS PureSee™ IOL is helping reshape outcomes in cataract surgery by offering patients high-quality, continuous vision without the typical compromises seen in other presbyopia-correcting lenses.
What Makes TECNIS PureSee™ IOL Different?
Traditionally, patients and surgeons have had to make trade-offs when choosing IOLs. Some premium lenses provide crisp vision at multiple distances but often introduce issues such as halos and glare, particularly at night. Others minimize these side effects but sacrifice near or intermediate clarity.
The TECNIS PureSee™ IOL is designed to reduce these compromises. It offers:
- Clear distance, intermediate, and functional near vision
- High contrast sensitivity even in low-light settings
- Visual outcomes comparable to monofocal IOLs
- Minimal halos and glares, leading to higher patient satisfaction
By addressing both the need for range of vision and visual comfort, it represents a step forward in presbyopia-correcting IOL technology.
Global Availability and Expansion
Currently, the TECNIS PureSee™ IOL is available across EMEA, APAC, Canada, and Latin America, with expansion plans underway, including eventual entry into the U.S. market. In addition, the TECNIS PureSee™ Toric II IOL, designed to treat patients with both presbyopia and astigmatism, is already available in select markets.
Recognition of Innovation
Peter Menziuso, Company Group Chairman, Vision at Johnson & Johnson, expressed pride in the recognition, stating that TECNIS PureSee™ provides surgeons and patients with a premium IOL option that delivers “uninterrupted high-quality vision” while reducing the common drawbacks seen in other designs.
The award underscores Johnson & Johnson’s long-standing commitment to advancing ophthalmic care and reflects its goal of “Vision Made Possible” for millions of people each year.
Why This Matters in Eye Care
By minimizing visual side effects while offering sharp vision across distances, this innovation has the potential to expand access to premium IOLs and reshape how cataract surgery is approached worldwide.
About the MedTech Breakthrough Awards
The MedTech Breakthrough Awards celebrate top companies and products across the global health and medical technology industry. In 2025, more than 4,500 nominations were received, making Johnson & Johnson’s recognition for the TECNIS PureSee™ IOL a significant milestone in ophthalmology innovation.
Sources: Johnson & Johnson Vision, MedTech Breakthrough Awards 2025
Discover more from An Eye Care Blog
Subscribe to get the latest posts sent to your email.
You must be logged in to post a comment.